Inari Medical, a leading medical device company focused on developing innovative solutions for the treatment of venous thromboembolism (VTE), has announced that it will be presenting at the 2024 Bank of America Securities Healthcare Conference. The conference, which will take place on May 14-16, 2024, will bring together industry leaders, investors, and analysts to discuss the latest trends and developments in the healthcare sector.
Inari Medical is scheduled to present on May 15, 2024, and will provide an overview of the company’s recent achievements, upcoming milestones, and growth strategy. The presentation will also cover Inari Medical’s flagship products, including the FlowTriever System and the ClotTriever System, which are designed to remove blood clots from the venous system and improve patient outcomes.
The FlowTriever System is a minimally invasive device that uses a unique mechanical mechanism to capture and remove large clot burdens from the pulmonary arteries, while the ClotTriever System is designed to remove clot burdens from peripheral veins. Both devices have been shown to be safe and effective in clinical studies, with high success rates and low complication rates.
Inari Medical has experienced rapid growth since its founding in 2012, with its products being used in over 10,000 procedures worldwide. The company has also received FDA clearance for several new indications and has expanded its presence in key markets such as Europe and Asia.
Inari Medical’s participation in the Bank of America Securities Healthcare Conference is a testament to its commitment to innovation and excellence in the field of VTE treatment. The company’s presentation will provide investors and stakeholders with valuable insights into its business strategy, market opportunities, and future growth prospects.
Overall, Inari Medical’s presence at the conference is expected to generate significant interest and excitement among attendees, as the company continues to make strides in advancing the standard of care for patients with VTE. Investors and analysts alike will be eagerly anticipating the company’s presentation and looking forward to hearing more about its promising pipeline of products and technologies.